Triple antiviral therapy in HCV positive patients who failed prior combination therapy

World Journal of Gastroenterology

Volumn 12, Issue 33, 2006, Pages 5293-5300

  Fargion, Silvia ^a   Borzio, Mauro ^b   Maraschi, Alessandra ^a   Cargnel, Antonietta ^c   Bolognini, Giovanni ^d   Benetti, Gian Piero ^e   Fracanzani, Anna Ludovica ^a   Pinzello, Giovanni ^f   Vinci, Maria ^f   Croce, Guido ^g   Capretti, Andrea ^g   Giorni, Riccardo ^c   Pozzi, Massimo ^h   Redaelli, Alessandro ^h   Prada, Alberto ⁱ   Omazzi, Barbara ⁱ   Autolitano, Aldo ^j   Del Poggio, Paolo ^k  

^a UNIVERSITY OF MILAN   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d General Hospital   (Italy)

^e Ospedale Predabissi   (Italy)

^f OSPEDALE NIGUARDA CA GRANDA   (Italy)

^g SAN CARLO BORROMEO HOSPITAL   (Italy)

^h SAN GERARDO HOSPITAL   (Italy)

ⁱ Uboldo Hospital   (Italy)

^j Asilo Vittoria Hospital   (Italy)

^k Caravaggio Hospital   (Italy)

more..

Author keywords

Amantadine; Hepatitis C; Nonresponders; Peginterferon; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; AMANTADINE; ANTIVIRUS AGENT; INTERFERON; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DRUG DOSE REGIMEN; DRUG EFFICACY; DYSPNEA; ERYTHEMA; FEMALE; GRANULOCYTOPENIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; INSOMNIA; LEUKOPENIA; LIVER DYSFUNCTION; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROPATHY; NEUTROPENIA; OPEN STUDY; PRURITUS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

EID: 33749415283     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i33.5293     Document Type: Article

References (45)

1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
3. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403
4. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-11672
5. Keeffe EB. Chronic hepatitis C: management of treatment failures. Clin Gastroenterol Hepatol 2005; 3: S102-105
6. Sethi A, Shiffman ML. Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response. Clin Liver Dis 2005; 9: 453-471, vii-viii
7. Gross JB. Non-responders to previous treatment for hepatitis C. Minerva Gastroenterol Dietol 2005; 51: 47-54
8. Cheng SJ, Bonis PA, Lau J, Pham NQ, Wong JB. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 2001; 33: 231-240
9. Cummings KJ, Lee SM, West ES, Cid-Ruzafa J, Fein SG, Aoki Y, Sulkowski MS, Goodman SN. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. JAMA 2001; 285: 193-199
10. Saracco G, Olivero A, Ciancio A, Carenzi S, Smedile A, Cariti G, Andreoni M, Orsi PG, Biglino A, Tabone M, Roffi L, Croce G, Manca A, Tappero G, Ciccone G, Rizzetto M. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. Hepatology 2002; 36: 959-966
11. Fargion S, Bruno S, Borzio M, Battezzati PM, Bissoli F, Ceriani R, Orlandi A, Maraschi A, Chiesa A, Morini L, Fracanzani AL, Crosignani A, Fiorelli G, Podda M. Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon. J Hepatol 2003; 38: 499-505
12. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493-1499
13. Hasan F, Al-Khaldi J, Asker H, Al-Ajmi M, Owayed S, Varghese R, Siddique I, Al-Nakib B. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin. Antivir Ther 2004; 9: 499-503
14. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015-1023; discussion 947
15. Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC Jr, Esposito SP, Brown RS Jr, Brau N, Klion FM, Tobias H, Bini EJ, Brodsky N, Cerulli MA, Aytaman A, Gardner PW, Geders JM, Spivack JE, Rahmin MG, Berman DH, Ehrlich J, Russo MW, Chait M, Rovner D, Edlin BR. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005; 100: 2453-2462
16. Marrache F, Consigny Y, Ripault MP, Cazals-Hatem D, Martinot M, Boyer N, Degott C, Valla D, Marcellin P. Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. J Viral Hepat 2005; 12: 421-428
17. Krawitt EL, Ashikaga T, Gordon SR, Ferrentino N, Ray MA, Lidofsky SD. Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol 2005; 43: 243-249
18. Wandinger KP, Hagenah JM, Kluter H, Rothermundt M, Peters M, Vieregge P. Effects of amantadine treatment on in vitro production of interleukin-2 in de-novo patients with idiopathic Parkinson's disease. J Neuroimmunol 1999; 98: 214-220
19. Skehel JJ, Hay AJ, Armstrong JA. On the mechanism of inhibition of influenza virus replication by amantadine hydrochloride. J Gen Virol 1978; 38: 97-110
20. Jubin R, Murray MG, Howe AY, Butkiewicz N, Hong Z, Lau JY. Amantadine and rimantadine have no direct inhibitory effects against hepatitis C viral protease, helicase, ATPase, polymerase, and internal ribosomal entry site-mediated translation. J Infect Dis 2000; 181: 331-334
21. Koff WC, Elm JL Jr, Halstead SB. Inhibition of dengue virus replication by amantadine hydrochloride. Antimicrob Agents Chemother 1980; 18: 125-129
22. Deltenre P, Henrion J, Canva V, Dharancy S, Texier F, Louvet A, De Maeght S, Paris JC, Mathurin P. Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J Hepatol 2004; 41: 462-473
23. Engler S, Flechtenmacher C, Wiedemann KH, Gugler R, Stremmel W, Kallinowski B. Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection. J Viral Hepat 2004; 11: 60-68
24. Thuluvath PJ, Maheshwari A, Mehdi J, Fairbanks KD, Wu LL, Gelrud LG, Ryan MJ, Anania FA, Lobis IF, Black M. Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naive patients with chronic hepatitis C. Gut 2004; 53: 130-135
25. Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000; 32: 630-634
26. Adinolfi LE, Utili R, Tonziello A, Ruggiero G. Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial. Gut 2003; 52: 701-705
27. Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 2001; 33: 704-707
28. Teuber G, Pascu M, Berg T, Lafrenz M, Pausch J, Kullmann F, Ramadori G, Arnold R, Weidenbach H, Musch E, Junge U, Wiedmann KH, Herrmann E, Zankel M, Zeuzem S. Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. J Hepatol 2003; 39: 606-613
29. Younossi ZM, Mullen KD, Hodnick S, Barnes DS, Carey WD, McCullough AC, Easley K, Gramlich T, Liebermann BY. Triple combination of interferon alpha-2b, ribavirin, and amantadine for treatment of chronic hepatitis C. J Clin Gastroenterol 2003; 36: 427-430
30. Stauber RE, Hofer H, Hackl F, Schutze K, Datz C, Hegenbarth K, Jessner W, Steindl-Munda P, Peter F. Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine. Wien Klin Wochenschr 2004; 116: 530-535
31. Thuluvath PJ, Pande H, Maygers J. Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin. Dig Dis Sci 2003; 48: 594-597
32. Oguz D, Cicek B, Filik L, Odemis B, Kilic M, Altintas E, Zengin N, Altiparmak E. Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C (genotype 1). World J Gastroenterol 2005; 11: 580-583
33. Maynard M, Pradat P, Bailly F, Rozier F, Nemoz C, Si Ahmed SN, Adeleine P, Trepo C. Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). J Hepatol 2006; 44: 484-490
34. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699
35. Zilly M, Lingenauber C, Desch S, Vath T, Klinker H, Langmann P. Triple antiviral re-therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine in nonresponders to interferon-alpha and ribavirin. Eur J Med Res 2002; 7: 149-154
36. Martin J, Navas S, Fernandez M, Rico M, Pardo M, Quiroga JA, Zahm F, Carreno V. In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients. Antiviral Res 1999; 42: 59-70
37. Camma C, Bruno S, Schepis F, Lo Iacono O, Andreone P, Gramenzi AG, Mangia A, Andriulli A, Puoti M, Spadaro A, Freni M, Di Marco V, Cino L, Saracco G, Chiesa A, Crosignani A, Caporaso N, Morisco F, Rumi MG, Craxi A. Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. Gut 2002; 51: 864-869
38. Mangia A, Leandro G, Helbling B, Renner EL, Tabone M, Sidoli L, Caronia S, Foster GR, Zeuzem S, Berg T, Di Marco V, Cino N, Andriulli A. Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. J Hepatol 2004; 40: 478-483
39. Ishida H, Inoue Y, Wong JB, Okita K. Cost-effectiveness of ribavirin plus interferon alpha-2b for either interferon relapsers or non-responders in chronic hepatitis C: a Japanese trial. Hepatol Res 2004; 28: 125-136
40. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, Fried MW, Purdum PP 3rd, Jensen D, Smith C, Lee WM, Boyer TD, Lin A, Pedder S, DePamphilis J. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-438
41. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-1680
42. Bruno S, Camma C, Di Marco V, Rumi M, Vinci M, Camozzi M, Rebucci C, Di Bona D, Colombo M, Craxi A, Mondelli MU, Pinzello G. Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 2004; 41: 474-481
43. Huber TJ, Dietrich DE, Emrich HM. Possible use of amantadine in depression. Pharmacopsychiatry 1999; 32: 47-55
44. Bacosi M, Russo F, D'innocenzo S, Santolamazza M, Miglioresi L, Ursitti A, De Angelis A, Patrizi F, Ricci GL. Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatol Res 2002; 22: 231-239
45. Trimoulet P, de Ledinghen V, Foucher J, Castera L, Fleury H, Couzigou P. Predictive value of early HCV RNA quantitation for sustained response in nonresponders receiving daily interferon and ribavirin therapy. J Med Virol 2004; 72: 46-51